Articles liés à Therapeutic Targeting of RAS Mutant Cancers

Therapeutic Targeting of RAS Mutant Cancers - Couverture souple

Stites, Edward C.

 
9781009073646: Therapeutic Targeting of RAS Mutant Cancers
Couverture souple
ISBN 10 : 1009073648 ISBN 13 : 9781009073646
Editeur : Cambridge University Press, 2022

Synopsis

The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Éditeur
Cambridge University Press
Date d'édition
2022
Langue
anglais
ISBN 10 
1009073648
ISBN 13 
9781009073646
Reliure
Broché
Nombre de pages
38
Coordonnées du fabricant
non disponible
Personne responsable
Avery
https://www.avery.fr/

chemin des peupliers 27
Dardilly
France